Canagliflozin improves obesity and insulin resistance in a diabetic patient with Cushing's disease undergoing postoperative steroid therapy: A case report

Nishihama,Kota; Furuta,Noriko; Maki,Kanako; Okano,Yuko; Hashimoto,Rei; Hotta,Yasuhiro; Uemura,Mei; Yasuma,Taro; Suzuki,Toshinari; D'alessandro-Gabazza,Corina N.; Yano,Yutaka; Gabazza,Esteban C.

doi:10.3892/br.2018.1153

Canagliflozin improves obesity and insulin resistance in a diabetic patient with Cushing's disease undergoing postoperative steroid therapy: A case report

Authors:
- Kota Nishihama
- Noriko Furuta
- Kanako Maki
- Yuko Okano
- Rei Hashimoto
- Yasuhiro Hotta
- Mei Uemura
- Taro Yasuma
- Toshinari Suzuki
- Corina N. D'alessandro-Gabazza
- Yutaka Yano
- Esteban C. Gabazza
View Affiliations

Affiliations: Department of Diabetes, Metabolism and Endocrinology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan, Department of Immunology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
Published online on: October 1, 2018 https://doi.org/10.3892/br.2018.1153
Pages: 497-502

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A 47-year-old woman with diabetes treated with high-dose insulin was admitted to Mie University Hospital, Tsu, Japan, for screening of secondary diabetes mellitus and obesity. Laboratory tests and imaging studies were consistent with Cushing's disease (CD). The patient underwent trans-sphenoidal pituitary surgery. The patient exhibited loss of body weight (85.9 to 80.0 kg), improved glycated hemoglobin (HbA1c) (11.2 to 7.8%) and required lower doses of insulin (112 to 46 U/day) 6 months after surgery. The patient's body weight and daily insulin dose remained stable during the following 5 months (6-11 months after surgery). At that point, the patient was administered with canagliflozin, a sodium-glucose cotransporter 2 inhibitor. The patient required lower daily insulin dose without decreasing the dose of postoperative hydrocortisone concurrent to the administration of canagliflozin (100 mg/day). The patient's body weight decreased to 69.5 kg and withdrawal of insulin therapy was possible 8 months after initiation of canagliflozin. Despite withdrawal of insulin therapy, the HbA1c levels remained at <7.0%. Although surgical treatment is the first-choice treatment for CD, obesity-related metabolic disorders including diabetes are frequent in CD patients following surgery. Canagliflozin may be an effective treatment to reduce body weight and improve insulin resistance following surgical treatment of CD.

View Figures

View References

1	Newell-Price J, Bertagna X, Grossman AB and Nieman LK: Cushing's syndrome. Lancet. 367:1605–1617. 2006. View Article : Google Scholar : PubMed/NCBI
2	Colao A, Boscaro M, Ferone D and Casanueva FF: Managing Cushing's disease: The state of the art. Endocrine. 47:9–20. 2014. View Article : Google Scholar : PubMed/NCBI
3	Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, et al: Incidence and late prognosis of Cushing's syndrome: A population-based study. J Clin Endocrinol Metab. 86:117–123. 2001. View Article : Google Scholar : PubMed/NCBI
4	Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO and Tabarin A; Endocrine Society, : Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 100:2807–2831. 2015. View Article : Google Scholar : PubMed/NCBI
5	Chanson P and Salenave S: Metabolic syndrome in Cushing's syndrome. Neuroendocrinology. 92 Suppl 1:96–101. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hassan-Smith ZK, Sherlock M, Reulen RC, Arlt W, Ayuk J, Toogood AA, Cooper MS, Johnson AP and Stewart PM: Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab. 97:1194–1201. 2012. View Article : Google Scholar : PubMed/NCBI
7	American Diabetes Association, . 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 41 Suppl 1:S13–S27. 2018. View Article : Google Scholar : PubMed/NCBI
8	Alberti KG, Zimmet P and Shaw J: Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 23:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kai H: Blood pressure management in patients with type 2 diabetes mellitus. Hypertens Res. 40:721–729. 2017. View Article : Google Scholar : PubMed/NCBI
10	Little RR and Rohlfing CL: The long and winding road to optimal HbA1c measurement. Clin Chim Acta. 418:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
11	Iwayama H, Hirase S, Nomura Y, Ito T, Morita H, Otake K, Okumura A and Takagi J: Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: Case report and literature review. BMC Endocr Disord. 18:192018. View Article : Google Scholar : PubMed/NCBI
12	Kageyama K, Oki Y, Sakihara S, Nigawara T, Terui K and Suda T: Evaluation of the diagnostic criteria for Cushing's disease in Japan. Endocr J. 60:127–135. 2013. View Article : Google Scholar : PubMed/NCBI
13	Melmed S and Jameson JL: HypopituitarismHarrison's Principles of Internal Medicine. 19th edition. McGraw-Hill Education; New York, NY: pp. 2255–2261. 2015
14	Fukuda I, Hizuka N, Nuraoka T and Ichihara A: Adult growth hormone deficiency: Current concepts. Neurol Med Chir (Tokyo). 54:599–605. 2014. View Article : Google Scholar
15	Newell-Price J, Morris DG, Drake WM, Korbonits M, Monson JP, Besser GM and Grossman AB: Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 87:1640–1645. 2002. View Article : Google Scholar : PubMed/NCBI
16	Pivonello R, De Martino MC, De Leo M, Simeoli C and Colao A: Cushing's disease: The burden of illness. Endocrine. 56:10–18. 2017. View Article : Google Scholar : PubMed/NCBI
17	Pivonello R, De Leo M, Cozzolino A and Colao A: The Treatment of Cushing's Disease. Endocr Rev. 36:385–486. 2015. View Article : Google Scholar : PubMed/NCBI
18	Geer EB, Shen W, Strohmayer E, Post KD and Freda PU: Body composition and cardiovascular risk markers after remission of Cushing's disease: A prospective study using whole-body MRI. J Clin Endocrinol Metab. 97:1702–1711. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bouclaous C, Torbay N, Nassar C and Hwalla N: Modification of glucocorticoid effects on body weight gain, plasma lipids by changes in diet composition. Nutr Res. 23:1105–1115. 2003. View Article : Google Scholar
20	Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG and Tamez-Peña AL: Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 6:1073–1081. 2015. View Article : Google Scholar : PubMed/NCBI
21	Sopjani M, Alesutan I, Wilmes J, Dërmaku-Sopjani M, Lam RS, Koutsouki E, Jakupi M, Föller M and Lang F: Stimulation of Na⁺/K⁺ ATPase activity and Na+ coupled glucose transport by β-catenin. Biochem Biophys Res Commun. 402:467–470. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, Day EA, Salt IP, Steinberg GR and Hardie DG: The Na⁺/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP Levels. Diabetes. 65:2784–2794. 2016. View Article : Google Scholar : PubMed/NCBI
23	Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB and Korbonits M: Changes in adenosine 5-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab. 93:4969–4973. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kelly J, Hunt BJ, Lewis RR, Swaminathan R, Moody A, Seed PT and Rudd A: Dehydration and venous thromboembolism after acute stroke. QJM. 97:293–296. 2004. View Article : Google Scholar : PubMed/NCBI
25	Yasui A, Lee G, Hirase T, Kaneko T, Kaspers S, von Eynatten M and Okamura T: Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes. Diabetes Ther. 9:863–871. 2018.PubMed/NCBI
26	Gelbenegger G, Buchtele N, Schoergenhofer C, Roeggla M and Schwameis M: Severe hypernatraemic dehydration and unconsciousness in a care-dependent inpatient treated with empagliflozin. Drug Saf Case Rep. 4:172017. View Article : Google Scholar : PubMed/NCBI
27	Andersen A, Lund A, Knop FK and Vilsbøll T: Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 14:390–403. 2018. View Article : Google Scholar : PubMed/NCBI
28	Cuevas-Ramos D, Lim DST and Fleseriu M: Update on medical treatment for Cushing's disease. Clin Diabetes Endocrinol. 2:162016. View Article : Google Scholar : PubMed/NCBI